3,4-Dihydro-6-isopropyl-4-methyl-2h-benzo[b][1,4]oxazin-7-ol | 865305-82-4

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并恶嗪类
• 英文名称: 3,4-Dihydro-6-isopropyl-4-methyl-2h-benzo[b][1,4]oxazin-7-ol
• 英文别名: 4-methyl-6-propan-2-yl-2,3-dihydro-1,4-benzoxazin-7-ol
• CAS: 865305-82-4
• 化学式: C₁₂H₁₇NO₂
• 分子量: 207.272
• InChiKey: VEISYNPBNJRJDS-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.6
• 重原子数：
  15
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  32.7
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为产物：
  描述：

  6-isopropyl-7-methoxy-4-methyl-3,4-dihydro-2H-benzo[1,4]oxazine 在 三溴化硼 作用下， 以 二氯甲烷 为溶剂， 反应 29.75h， 生成 3,4-Dihydro-6-isopropyl-4-methyl-2h-benzo[b][1,4]oxazin-7-ol
  参考文献：
  名称：

  Methods of using diaminopyrimidine P2X3 and P2X2/3 receptor modulators for treatment of respiratory and gastrointestinal diseases

  摘要：

  用于治疗由P2X3和/或P2X2/3受体拮抗剂介导的呼吸系统和胃肠道疾病的方法，包括向有此需要的受试者施用有效量的式(I)化合物：或其药学上可接受的盐，其中D、X、Y、R1、R2、R3、R4、R5、R6、R7和R8如本文所定义。

  公开号：

  US20070049609A1

文献信息

• Diaminopyrimidines as P2X3 and P2X2/3 antagonists
  申请人：Broka Allen Chris

  公开号：US20050209260A1

  公开（公告）日：2005-09-22

  Compounds and methods for treating diseases mediated by a P2X 3 and/or a P2X 2/3 receptor antagonist, the methods comprising administering to a subject in need thereof an effective amount of a compound of formula (I): or a pharmaceutically acceptable salt, solvate or prodrug thereof, wherein D, X, Y, R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 and R 8 are as defined herein.

  用于治疗由P2X3和/或P2X2/3受体拮抗剂介导的疾病的治疗化合物和方法，该方法包括向有需要的受试者施用有效量的式I化合物：或其药学上可接受的盐、溶剂化物或前药，其中D、X、Y、R1、R2、R3、R4、R5、R6、R7和R8如本文所定义。
• DIAMINOPYRIMIDINES AS P2X3 AND P2X2/3 ANTAGONISTS
  申请人：Broka Chris Allen

  公开号：US20110077242A1

  公开（公告）日：2011-03-31

  Compounds and methods for treating diseases mediated by a P2X 3 and/or a P2X 2/3 receptor antagonist, the methods comprising administering to a subject in need thereof an effective amount of a compound of formula (I): or a pharmaceutically acceptable salt, solvate or prodrug thereof, wherein D, X, Y, R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 and R 8 are as defined herein.

  本发明涉及化合物和方法，用于治疗由P2X3和/或P2X2/3受体拮抗剂介导的疾病，其中所述方法包括向需要该治疗的受体中施用化合物I式的有效量，或其药学上可接受的盐、溶剂或前药，其中D、X、Y、R1、R2、R3、R4、R5、R6、R7和R8如本文所定义。
• METHODS OF USING DIAMINOPYRIMIDINE AS P2X3 AND P2X2/3 RECEPTOR MODULATORS FOR TREATMENT OF RESPIRATORY AND GASTROINTESTINAL DISEASES
  申请人：Broka Chris Allen

  公开号：US20120122859A1

  公开（公告）日：2012-05-17

  Methods for treating respiratory and gastrointestinal diseases mediated by a P2X 3 and/or a P2X 2/3 receptor antagonist, the methods comprising administering to a subject in need thereof an effective amount of a compound of formula (I): or a pharmaceutically acceptable salt thereof, wherein D, X, Y, R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 and R 8 are as defined herein.

  治疗由P2X3和/或P2X2/3受体拮抗剂介导的呼吸道和胃肠道疾病的方法，包括向需要治疗的个体施用式(I)的化合物的有效量或其药学上可接受的盐，其中D、X、Y、R1、R2、R3、R4、R5、R6、R7和R8如此定义。
• METHODS OF USING DIAMINOPYRIMIDINE P2X3 AND P2X2/3 RECEPTOR MODULATORS FOR TREATMENT OF RESPIRATORY AND GASTROINTESTINAL DISEASES
  申请人：Roche Palo Alto LLC

  公开号：US20130225570A1

  公开（公告）日：2013-08-29

  Methods for treating respiratory and gastrointestinal diseases mediated by a P2X 3 and/or a P2X 2/3 receptor antagonist, the methods comprising administering to a subject in need thereof an effective amount of a compound of formula (I): or a pharmaceutically acceptable salt thereof, wherein D, X, Y, R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 and R 8 are as defined herein.

  治疗通过P2X3和/或P2X2/3受体拮抗剂介导的呼吸道和胃肠道疾病的方法，包括向需要该治疗的受体中投与有效量的化合物I式的药物或其药学上可接受的盐，其中D，X，Y，R1，R2，R3，R4，R5，R6，R7和R8如本文所定义。
• DIAMINOPYRIMIDINES AS P2X3 AND P2X2/3 MODULATORS
  申请人：F.Hoffmann-La Roche AG

  公开号：EP1924264B1

  公开（公告）日：2013-09-18